Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Optimism for Taysha Gene Therapies: Promising Preclinical Data and Upcoming Catalysts Drive Buy Rating
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Truist Financial Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7
Taysha Gene Therapies Analyst Ratings
Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Maintained Buy Rating on Taysha Gene Therapies Amid Progress and Solid Financials
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Buy Rating Affirmed for Taysha Gene Therapies Amid Strong Financials and Promising Clinical Trials
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $8
Truist Financial Remains a Buy on Taysha Gene Therapies (TSHA)
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)
Buy Rating Justified by Taysha Gene Therapies' Clinical Advances and Extended Financial Runway
Needham Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Taysha Gene Therapies Analyst Ratings
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target